Podcasts about ckd

In Episode 142 of Diary of a Kidney Warrior Podcast, host Dee Moore sits down with Dr. Vikram Talaulikar—menopause specialist and Associate Professor in Women's Health—to demystify menopause for people living with chronic kidney disease (CKD).   If you've ever wondered whether changing periods, brain fog, poor sleep, hot flushes, joint aches or low mood are “just stress,” menopause, or CKD—this conversation is for you. We explore the menopause transition (perimenopause → menopause → postmenopause), how symptoms can overlap with CKD, and what practical steps you can take right now.   You'll hear about: •Perimenopause vs. menopause—what's normal, what to track, and why one blood test often doesn't tell the full story. •Lifestyle strategies that genuinely help (sleep hygiene, movement, nutrition, supplements to discuss with your team). •Non-hormonal options (including CBT and certain medications) and when they may be considered. •HRT in CKD—safer formulations, delivery routes, and the “lowest effective dose” principle to discuss with your clinicians. •Bone and heart health during and after the transition—and what to raise at your next appointment. •Why timely support matters and how to build a joined-up plan with your GP, kidney team, or menopause specialist.   This episode is compassionate, practical, and designed to help you advocate for yourself. We're also preparing a listener-led Q&A with Dr. Talaulikar—send us your questions! Submission details are in the show notes.   Perfect for: Women with CKD (or their supporters) navigating menopause, perimenopause, postmenopause; anyone curious about evidence-based options—including HRT—in the context of kidney health.     Follow & Subscribe: If this helped you, follow the show, leave a review, and share with a fellow Kidney Warrior. Your support helps more people find life-changing information.     Follow Diary of a Kidney Warrior:  

Welcome back to the Hot Topics podcast from NB Medical with Dr Neal Tucker. In this new season, we chat to Dr Simon Curtis about the upcoming Autumn 2025 Hot Topics course, then discuss three new pieces of research.First, in the Lancet, which are the best anti-hypertensives, what effect does increasing a dose actually have and how good are combinations? Second, in the NEJM, does giving all the drugs improve CKD outcomes? The case for finerenone and empagliflozin. Third, do ADHD drugs help outcomes beyond core symptoms such as accidents, suicide and crime? But can we rely on the research method used...?ReferencesLancet Antihypertensive Efficacy PaperNEJM Finerenone & EmpagliflozinReport on trends in CKDBMJ ADHD meds & prevention of complicationswww.nbmedical.com/podcast

GLP-1 medications like Ozempic were designed to treat diabetes—but they're quickly becoming known for weight loss and possible kidney benefits. Kidney doctor Holly Kramer and kidney patients Patrick Gee, and Jane DeMeis, are here to break down what these medications are, how they work, and what people with kidney disease need to know.   In today's episode we heard from: Holly Kramer, M.D., MPH, is a practicing nephrologist who conducts research connecting nutrition and kidney health. Her connection to the National Kidney Foundation was inspired by her mom, who was a dialysis nurse and helped create some of the first dialysis units in Northwest Indiana. Dr. Kramer finds being on the NKF Board important, because it is the largest, patient-centered organization focusing on kidney disease. Her long-term goal is to increase national funding for kidney disease research and to heighten awareness about chronic kidney disease. Jane DeMeis  became involved with the National Kidney Foundation when she was diagnosed in 2018 with stage 4 kidney disease. She is currently on home hemodialysis and the transplant waitlist. Ms. DeMeis was the Director of Education and Organizational Development for U R Medicine Home Care. Part of her responsibilities was working with clinicians in teaching them how to present education to patients. She also was the Chairperson of the Patient Family Centered Care program and worked with improving home care through patient advocacy.  In 2018, Ms. DeMeis retired. She had been fighting CKD along with Psoriatic Arthritis for many years and needed to focus on her health.  She currently serves as a member of NKF's Kidney Advocacy Committee, as an Ambassador for NKF's online communities, and also as a NKF Peer mentor. Her other volunteer activities include being on the Board of the Perinton Food Shelf and working with clients as the Lead Verifier.  She and her husband sing with the Perinton Senior Chorus and enjoy working in their garden. Patrick Gee is a Community Activist, fighting against systemic issues such as poverty, social and racial injustices, criminal justice reform, and education reform. Patrick worked for the Virginia Department of Corrections and the Virginia Department of Juvenile Justice, where during his time in service, he acquired several awards and recognitions. In April 2013, Patrick was diagnosed with Stage 3b End-Stage Kidney Disease (ESKD). He began doing Peritoneal Dialysis (PD) in December 2013. On April 21, 2017, Patrick received a kidney transplant. Patrick has been very passionate in his pursuit to speak on behalf of the underserved, undervalued, and disenfranchised communities of color. Because of this, he serves as an advocate and kidney patient expert for a number of organizations including the NKF, CMS, FDA, KHI, AKF, AAKP and HDU.  Patrick was the 2025 winner of NKF's Celeste Lee Castillo Patient Engagement Award.    Additional Resources: GLP-1 Receptor Agonists NKF Supports Proposal to Expand Access to Weight-Loss Medications   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Potassium is a HOT topic in kidney disease - but doesn't get the focus is deserves for kidney stones. In This episode, Melanie breaks down potassium in your diet, where it comes from and why it matters for both kidney disease AND kidney stones.  Blog: Potential Renal Acid Load Blog: Potatoes & Kidney Disease: The Potassium Dilemma References: 1. Ikizler A, Burrowes J, Byham-Gray L, et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am J Kidney Dis. 2020;76(3):S1-S107. 2. MacLaughlin HL, McAuley E, Fry J, et al. Re-Thinking Hyperkalaemia Management in Chronic Kidney Disease—Beyond Food Tables and Nutrition Myths: An Evidence-Based Practice Review. Nutrients. 2024;16(1):3.    Submit a question for Melanie to answer on the podcast! Connect with The Kidney Dietitian! Work with Us! |  Instagram | Facebook | Pinterest | Facebook Group | Newsletter www.thekidneydietitian.org FREE Webinar: The 3-Step Method to Prevent Kidney Stones All information in this podcast is meant for educational purposes only and should not be used in place of advice from a medical professional.  

Welcome to another eye-opening episode of Transforming Relationships with Emotional Intelligence, where we explore the connection between emotional well-being, physical health, and the everyday relationships that shape our lives.In this vital conversation, I'm joined by a compassionate and highly experienced renal nurse (Roseline Elsie Agyekum), who sheds light on one of the most overlooked but essential parts of the body—our kidneys.Together, we explore the emotional, clinical and lifestyle aspects of chronic kidney disease (CKD)—a condition that affects millions globally but often goes undetected until it's too late. Whether you're living with chronic illness, caring for someone who is, or simply want to take better care of your health, this episode will equip you with insights and practical steps to protect your kidneys and overall well-being. In This Episode, You'll Discover:What your kidneys actually do—and why they're critical to your full-body healthThe biggest risk factors for CKD, including diabetes, hypertension, obesity, and medicationsSubtle early signs that your kidney health may be at riskPractical, evidence-based strategies for protecting your kidneys through lifestyle changesWhat patients with high blood pressure or diabetes must know to safeguard kidney functionLesser-known risks to kidney health—like certain medications and habitsHow social, environmental, and systemic factors influence kidney health and health equityThis episode is a call to awareness and a reminder that health is built in both the clinic and the community. It's a powerful invitation to take control of your health with clarity, compassion and confidence.Tune in now to gain the knowledge and motivation you need to support your kidneys and the people you care about.Work With Coach OwenicoIf you're ready to explore how emotional intelligence can transform your leadership, wellbeing, or relationships:→ Book a free private call: www.calendly.com/owenicoconsult→ Email me directly: owen@owenicoconsult.comStay ConnectedConnect with Coach Owenico: https://linktr.ee/owenicoconsultJoin our community & get free resources: Emotional Intelligence HubIf this episode inspired you, please subscribe, rate, and review—so we can continue sharing meaningful conversations that heal, inform, and empower.#Podcast #KidneyHealth #CKD #ChronicIllness #PreventiveHealth #EmotionalIntelligence #HealthAwareness #CoachOwenico #TransformingRelationships #Wellbeing #RenalNurse #HealthyHabits #HealthEquitySupport the show

Welcome to another eye-opening episode of Transforming Relationships with Emotional Intelligence, where we explore the connection between emotional well-being, physical health, and the everyday relationships that shape our lives.In this vital conversation, I'm joined by a compassionate and highly experienced renal nurse (Roseline Elsie Agyekum), who sheds light on one of the most overlooked but essential parts of the body—our kidneys.Together, we explore the emotional, clinical and lifestyle aspects of chronic kidney disease (CKD)—a condition that affects millions globally but often goes undetected until it's too late. Whether you're living with chronic illness, caring for someone who is, or simply want to take better care of your health, this episode will equip you with insights and practical steps to protect your kidneys and overall well-being.In This Episode, You'll Discover:What your kidneys actually do—and why they're critical to your full-body healthThe biggest risk factors for CKD, including diabetes, hypertension, obesity, and medicationsSubtle early signs that your kidney health may be at riskPractical, evidence-based strategies for protecting your kidneys through lifestyle changesWhat patients with high blood pressure or diabetes must know to safeguard kidney functionLesser-known risks to kidney health—like certain medications and habitsHow social, environmental, and systemic factors influence kidney health and health equityThis episode is a call to awareness and a reminder that health is built in both the clinic and the community. It's a powerful invitation to take control of your health with clarity, compassion and confidence.Tune in now to gain the knowledge and motivation you need to support your kidneys and the people you care about.Work With Coach OwenicoIf you're ready to explore how emotional intelligence can transform your leadership, wellbeing, or relationships:→ Book a free private call: www.calendly.com/owenicoconsult→ Email me directly: owen@owenicoconsult.comStay ConnectedConnect with Coach Owenico: https://linktr.ee/owenicoconsultJoin our community & get free resources: Emotional Intelligence HubIf this episode inspired you, please subscribe, rate, and review—so we can continue sharing meaningful conversations that heal, inform, and empower.#Podcast #KidneyHealth #CKD #ChronicIllness #PreventiveHealth #EmotionalIntelligence #HealthAwareness #CoachOwenico #TransformingRelationships #Wellbeing #RenalNurse #HealthyHabits #HealthEquitySupport the show

Resources:  Rutherford Chapters (10th ed.): 174, 175, 177, 178 Prior Holding Pressure episode on AV access creation: https://www.audiblebleeding.com/vsite-hd-access/ The Society for Vascular Surgery: Clinical practice guidelines for the surgical placement and maintenance of arteriovenous hemodialysis access: https://www.jvascsurg.org/article/S0741-5214%2808%2901399-2/fulltext  KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update: https://pubmed.ncbi.nlm.nih.gov/32778223/    Venous Hypertension   Definition A functioning AV circuit delivers high volume arterial flow towards a stenotic venous segment, causing buildup in pressure and venous hypertension. If there are few or no branching veins between the access and stenosis, thrombosis could occur   Etiology The most common etiology is venous stenosis caused by a history of vessel wall trauma by centrally-inserted venous devices such as tunneled and non-tunneled dialysis catheters, central lines, pacemakers, or defibrillator. In a study performed at a large academic medical center1, new hemodynamically significant central venous stenosis was associated with the duration of catheter dependence (26% in patients with CVCs for more than 6 months, versus 11% in patients with CVCs for less than 6 months). PICC lines can directly damage cephalic and basilic veins Venous stenosis can often go undetected until AV access creation occurs   Patient Presentation Symptoms of venous insufficiency will be present– most commonly regional edema, in the area of venous stenosis. If there are patent venous branches between the AV anastomosis and the stenotic area, swelling can occur throughout the arm. Pigmentation, induration, dermatosclerosis, and ulceration may also be observed. An extensive collateral network of veins may be visible throughout anterior chest, shoulder, or flank SVC obstruction can result in swelling of the head, neck and shoulders, as well as a feeling of head and neck fullness, airway compromise, and visual problems Normal palpable thrill can be replaced by a strong pulse Dialysis can be complicated by difficulty with needle access, recirculation syndrome, and arm swelling after dialysis sessions. Workup  Central vein thrombosis can be hard to detect on ultrasound because clavicle and sternum can block transmission Venography is essential to determine the presence and severity of venous stenosis or occlusion.   Prevention The ideal scenario is to avoid central dialysis catheters completely, and this involves evaluating CKD patients and placing AVF or AVG before the need for dialysis arises.  If a patient presents placement of an AVF/AVG, it is important to perform venography if a patient has a history of a central venous catheter or clinical signs of venous hypertension. A history of SVC obstruction from any cause can preclude permanent AV access creation in both upper extremities Treatment Endovascular approaches to venous outflow stenosis can be first-line treatment options, due to their minimal risk. They can also be performed at the same time as a diagnostic venogram. Angioplasty alone or with stenting are the endovascular options. In a study by Bakken et al2 that compared primary high-pressure balloon angioplasty versus stenting, primary patency was equivalent between groups, with 30-day rates of 76% for both groups and 12-month rates of 29% for angioplasty and 21% for stenting. Assisted primary patency was also equivalent with a 30-day patency rate of 81% and 12-month rate of 73% for the angioplasty group,  84% at 30 days, and 46% at 12 months for the stenting group. This study, along with others, shows that the major downside of endovascular interventions, whether angioplasty or stenting, often require repeat intervention and have poor long-term patency. For subclavian vein stenosis, angioplasty alone is appropriate due to its anatomical location that can put a stent at risk for extrinsic compression from the first rib and clavicle. Surgical bypass can be performed Possible bypasses include axillary-axillary, axillary-jugular, axillary-right atrial, and axillary-femoral. In these bypasses, the preferred conduits are autogenous saphenous or femoral veins. In cases where the proximal subclavian vein is obstructed, a jugular vein turndown can be performed. In this procedure the distal jugular vein is transected, sewed end-to-side at the distal subclavian vein, effectively acting as a bypass route for that obstructed segment. The Hemoaccess Reliable Outflow (HeRO) Vascular Access Device can be used as a hybrid approach, combining endovascular and open surgical techniques to bypass a central venous occlusion  and provide a reliable outflow for dialysis.  This device has a PTFE inflow limb that is sewn end-to-side onto the brachial artery. This limb is tunneled subcutaneously and connected to a silicone-coated nitinol outflow catheter that is inserted into a central vein and tracked directly into the right atrium. This effectively bypasses central venous stenoses. In the largest study to date on HeRO access grafts placed in 167 patients,3 HeRO primary and secondary patency was 48.8% and 90.8%, respectively, at 12 months. Interventions to maintain or re-establish patency were required in 71.3% of patients resulting in an intervention rate of 1.5/year. Access-related infections were reported in 4.3% patients. The authors concluded that HeRO device had performed comparably to standard AVGs and had proven superior to tunneled dialysis catheters in terms of patency, intervention, and infection rates. If no treatment options for venous hypertension or outflow obstruction  are available, an alternate AV access site can be created, either in the contralateral arm if the SVC is uninvolved, or through placement of femoral AV access or a peritoneal dialysis catheter.   Bleeding Access Site   Etiology and Risk Factors Bleeding can be caused by high venous pressure after dialysis, pseudoaneurysm rupture, or trauma. Patients with end stage renal disease (ESRD) have a baseline elevated risk of bleeding due to uremia-induced platelet dysfunction and use of systemic anticoagulation within the hemodialysis circuit. Additional risk factors include dialysis through an AV graft, hypertension, longer duration of access use, and compromised integrity of the vascular access due to complications (clotting, infection) or invasive procedures. Dual antiplatelet therapy is also associated with overall bleeding events in ESRD patients. Dialysis patients could be on antiplatelet therapy for management of comorbid cardiovascular risk and/or patency of AV graft Patients with bleeding fistulas often present from their dialysis unit when standard digital pressure at the cannulation site fails to stop the bleeding. This is a very serious condition since most mature fistulas have high blood flow and the patients are at risk for hemorrhagic shock and death.    Initial Management  The first step of management is to obtain hemostasis. Elevate the limb above the level of the heart and apply firm and directed pressure at the site of bleeding using gauze for at least 30-40 minutes Milosevic et al4 reviewed non-operative management of bleeding fistulas and grafts and found that compared to standard dressings, the use of specialized hemostatic dressings decreased bleeding time at arterial and venous cannulation sites. These hemostatic materials included the IRIS compression bandage and cellulose-based, chitosan-based, poly-N-acetyl glucosamine-based, and thrombin-soaked dressings. There has been a “bottlecap method” described where the hollow side of a bottlecap is pressed on top of the puncture site. Maintaining pressure on the cap will cause the cap to fill with blood and clot, which tamponades the bleeding. The provider can also place a shallow figure-of-8 or purse string stitch just below the skin surface to aid in hemostasis. It is important to avoid placing the suture too deep as this can cause inadvertent fistula ligation. During this process, an assistant applies pressure just proximal and distal to the bleeding site to stop blood flow so the sutures can be placed. If these methods fail to achieve hemostasis, apply a tourniquet proximal to the fistula and tighten it until bleeding stops and the radial pulse is lost. This signifies complete occlusion of arterial inflow to the fistula. Tourniquet use should be limited to 3 hours or less, since limb ischemia beyond this timepoint is associated with permanent neuromuscular damage. Regardless of the method used for initial hemostasis, the patient is at risk for repeat hemorrhage, hematoma formation, vessel stenosis, and thrombosis. They should be evaluated by a vascular surgeon as soon as possible.  Definitive Management Definitive management depends on etiology of each case, and there are a variety of interventions that can be pursued (i.e. aneurysmorrhaphy for aneurysmal bleeding) If skin erosion over the conduit is present, it should be assumed that the AV access is infected and emergency intervention should be pursued. A jump graft can be placed through with healthy tissue.  A covered stent could be introduced through a separate percutaneous puncture site Finally, coagulopathy can be addressed by administering cryoprecipitate, DDAVP, erythropoietin, estrogen, tranexamic acid. Aneurysms and Pseudoaneurysms   Definition and Etiology Aneurysms involve all three layers of the vessel wall and they develop due to hemodynamic changes causing remodeling of the vein wall in an AV fistula. This is necessary for vein maturation, but becomes problematic if the post-anastomotic vein continues to dilate and becomes aneurysmal.  Aneurysms can also occur at anastomosis sites due to technical aspects of the surgery. Pseudoaneurysms only involve some layers of the vessel wall caused by repeated puncture for hemodialysis.  Both aneurysms and pseudoaneurysms can enlarge due to venous outflow stenosis causing increased intraluminal pressures. Both true aneurysms and pseudoaneurysms can lead to overlying skin erosion and subsequent hemorrhage, pain, AV access dysfunction, and cannulation difficulties.  Dialysis cannulation should be avoided at the aneurysmal sites to prevent bleeding complications. Diagnosis They can be diagnosed on ultrasound, which also provide information on flow rates, presence inflow/outflow/stenoses, and vessel diameters.  Indications for Treatment Treatment is indicated for aneurysms that are rapidly expanding or ulcerating through the skin surface. These are at high risk for rupture and hemorrhage, which is life-threatening. Treatment is also indicated when the aneurysm occurs at the anastomotic site of the AV fistula, the patient has a cosmetic concern, cannulation becomes difficult, there is concern for infection, or the patient has high-output heart failure that could be exacerbated by high flow through the fistula. Treatment is not indicated in asymptomatic aneurysms, regardless of their size. True  aneurysms and pseudoaneurysms are not prone to spontaneous rupture.   Treatment Options Aneurysmorrhaphy is the most common treatment. It involves the resection of the aneurysmal vein wall to restore a normal diameter and removal of excess skin. Anastomosis is performed along the lateral wall to prevent issues with cannulation along the suture line. Aneurysm resection with interposition grafting is also possible. If multiple aneurysmal segments require treatment, staging their repairs can allow for continuation of dialysis without needing to place a temporary dialysis catheter. AV access ligation is an appropriate alternative to AV access salvage in certain situations but usually requires excision of the aneurysm/pseudoaneurysm due to the potential to develop thrombophlebitis and the cosmetic appearance of the thrombosed segment. If there is concern for an infected pseudoaneurysm or aneurysm, surgery should include removal of all infected material. References   1. Al-Balas A, Almehmi A, Varma R, Al-Balas H, Allon M. De Novo Central Vein Stenosis in Hemodialysis Patients Following Initial Tunneled Central Vein Catheter Placement. Kidney360. 2022;3(1):99-102. doi:10.34067/KID.0005202021 2. Bakken AM, Protack CD, Saad WE, Lee DE, Waldman DL, Davies MG. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients. J Vasc Surg. 2007;45(4):776-783. doi:10.1016/j.jvs.2006.12.046 3. Gage SM, Katzman HE, Ross JR, et al. Multi-center Experience of 164 Consecutive Hemodialysis Reliable Outflow [HeRO] Graft Implants for Hemodialysis Treatment. Eur J Vasc Endovasc Surg. 2012;44(1):93-99. doi:10.1016/j.ejvs.2012.04.011 4. Milosevic E, Forster A, Moist L, Rehman F, Thomson B. Non-surgical interventions to control bleeding from arteriovenous fistulas and grafts inside and outside the hemodialysis unit: a scoping review. Clin Kidney J. 2024;17(5):sfae089. doi:10.1093/ckj/sfae089

In this podcast, expert Suneel Udani, MD, discusses the management of chronic kidney disease (CKD) and CKD-associated fluid overload, including an overview of treatment guidelines and various available therapies.

How do you know when your kidney health needs more than GP care—and how can you make sure you're getting the right tests, referrals, and treatment?   In this powerful follow-up to Episode 139, host Dee Moore is once again joined by Dr. Kristin Veighey for Part 2 of “Beyond the GP: Making Primary Care Work for Kidney Health.” Together, they dive deeper into the realities of managing chronic kidney disease (CKD) in the primary care setting, giving patients the tools to advocate for themselves and get the support they need.   This episode answers the questions so many patients ask but rarely get clear guidance on:   ✅ Know your risk factors – from diabetes, high blood pressure, and heart disease to family history and medications that can affect kidney function. ✅ Why urine tests matter – and why they often reveal problems years before blood tests. ✅ Diabetes and CKD – the number one cause of kidney disease in the UK, and why tighter blood pressure, cholesterol, and glucose targets are essential. ✅ When to push for referral – understanding the Kidney Failure Risk Equation (KFRE), what “CKD stage 4 or 5” really means, and why you don't have to wait until dialysis is on the table. ✅ The role of the multidisciplinary team – how pharmacists, nurses, and other professionals in primary care can help streamline your care and reduce unnecessary appointments. ✅ Targets that protect your kidneys – the real numbers you should be aiming for with blood pressure, cholesterol, and blood sugar.  

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Daniel W. Coyne, MD, and Morgan B. Schoer, MD, about their editorial "Parathyroidectomy for Treatment of Hyperparathyroidism in CKD" from nephSAP Volume 24, Number 3.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Daniel W. Coyne, MD, and Morgan B. Schoer, MD, about their editorial "Parathyroidectomy for Treatment of Hyperparathyroidism in CKD" from nephSAP Volume 24, Number 3.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 10-16, 2025: FDA Approves 2 Generic Iron Sucrose Injections for Iron Deficiency Anemia in CKD  The FDA approved 2 generic versions of iron sucrose injection for treating iron deficiency anemia in patients with CKD, expanding access to therapy. FDA Approves PharmaTher's Ketamine for Surgical Pain Management  The FDA approved PharmaTher's ketamine formulation for surgical pain management following resolution of earlier application deficiencies. HFSA and ASPC Release Statement on Shifting to Prevention in Heart Failure  The HFSA and ASPC issued a joint statement urging clinicians to prioritize prevention and early risk management in heart failure care. Zopapogene Imadenovec First Immunotherapy Approved for Recurrent Respiratory Papillomatosis  The FDA approved zopapogene imadenovec as the first immunotherapy for recurrent respiratory papillomatosis, offering a new treatment option. AHA & ACC Release New Guidelines for High Blood Pressure to Reduce CVD Risk  The AHA and ACC released updated hypertension guidelines recommending earlier intervention to lower cardiovascular disease risk.

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Today, we're diving into one of the most talked-about topics in health and weight loss right now: GLP-1 medications like semaglutide and the newer dual GIP/GLP-1s like tirzepatide. You've probably seen the headlines, scrolled past a few TikToks, or heard a friend mention it — but with all that noise comes a lot of confusion, half-truths, and flat-out myths. Today we're breaking it all down. What's real? What's hype? And what do you actually need to know if you're using these medications — or thinking about it? Let's separate science from scare tactics and get to the truth, one myth at a time. Myth #1: GLP-1s Cause Dangerous Muscle Loss The claim:  “GLP-1s cause massive muscle loss.” Truth: This is an overstatement. Some loss of lean mass is normal with any kind of weight loss — whether it's through diet, medication, or surgery. What studies show is that with medications like semaglutide (Wegovy) and tirzepatide (Zepbound), about 20–25% of the total weight lost comes from lean mass, and the rest is fat — which is exactly what we're targeting in obesity treatment. That 20–25% figure isn't unique to these meds; it's actually pretty typical in weight loss without focused resistance training or optimized protein intake. You may also hear “You'll lose all your muscle and become frail on GLP-1s.” Truth: You won't “lose all your muscle.” In fact, muscle loss is preventable by maintaining adequate protein intake, resistance training, and managing weight loss pace. Furthermore, many patients gain strength and mobility as excess weight comes off. And lastly, my favorite myth is “You can't preserve muscle on GLP-1s.” Truth: That's completely false — muscle loss isn't inevitable on GLP-1s if you take the right approach. You can absolutely preserve muscle by making a few intentional choices: aim for enough protein each day (a good goal is around 0.8 grams per pound of body weight), include some strength or resistance training a couple times a week, and avoid losing weight too quickly. These simple steps go a long way in protecting your lean mass while still getting all the benefits of weight loss. One study on semaglutide showed that people lost an average of about 15% of their body weight, and only around 3–4% of that was lean mass. So if someone drops 30 pounds, maybe 6 to 8 of those pounds might be lean mass—not ideal, but definitely not disastrous either, and very manageable with the right lifestyle habits.  The truth is, while some lean mass loss is expected with any type of weight loss, research shows that most of the weight lost on GLP-1s is actually fat, not muscle. For example, in the STEP 1 trial, about 80% of the weight lost on semaglutide came from fat, and only about 20% from lean tissue (as we mentioned earlier).  The SURMOUNT-1 trial with tirzepatide showed similar results—significant fat loss with relatively preserved muscle, especially when paired with resistance training. And that's important, because preserving muscle during weight loss helps protect metabolism, strength, and overall health. With good nutrition and movement, GLP-1s can lead to healthier body composition—not just a lower number on the scale. Okay, moving along to the next myth … Myth #2: GLP-1s Can Cause Blindness The truth: This myth stems from concerns about diabetic retinopathy worsening, which is tied to how quickly blood sugar drops, not to the drug itself. In the SUSTAIN-6 trial (Marso et al., NEJM, 2016), a small subset of patients with pre-existing advanced diabetic retinopathy saw transient worsening—but only in those with rapid improvements in A1c. No increased rates of blindness or new-onset retinopathy have been found in non-diabetic patients using GLP-1s for weight loss. The bottom line is that those without advanced diabetic eye disease, there's no increased risk of blindness. Patients with diabetic retinopathy should be monitored closely—but this is about glycemic management, not a direct effect of the medication. Myth #3: GLP-1s Cause Kidney or Liver Damage The truth: This is false. In fact, GLP-1 agonists may protect kidney and liver function—especially in patients with diabetes or fatty liver disease. The most recent notable study showing kidney‑protective effects of a GLP‑1 receptor agonist is the FLOW trial, which evaluated semaglutide in people with type 2 diabetes and chronic kidney disease (CKD). This double‑blind, randomized, placebo‑controlled trial included 3,533 participants followed for a median of 3.4 years and found that semaglutide reduced the risk of major kidney‑related events—including kidney failure, substantial eGFR decline, and death from renal or cardiovascular causes—by 24% compared to placebo. A 2025 meta-analysis of multiple randomized controlled trials (11 studies, 85,373 participants) concluded that GLP‑1 receptor agonists reduced the risk of composite kidney failure outcomes by 18%, kidney failure by 16%, and all‑cause death by 12%. And let's not forget the SMART trial, involving obese patients with kidney disease but without diabetes, found that semaglutide protected kidney function in this non‑diabetic, CKD‑affected population.  When it comes to the liver, there's actually growing evidence they're actually helping reverse non-alcoholic fatty liver disease (NAFLD). The STEP 1 MRI substudy and SURPASS-3 MRI substudy have shown people on these medications can reduce liver fat by 30 to even 50% and in some cases, completely resolve liver inflammation — that more serious form called NASH, where fat is combined with inflammation and early scarring. The LEAN trial found that nearly 60% of people taking semaglutide had resolution of NASH, without worsening their liver scarring. That's huge. And even better, we're seeing these effects even in people who don't have diabetes. Just losing weight helps fatty liver, but these meds seem to do more than that — they actually target inflammation and fat storage in the liver itself.. The bottom line is GLP-1s are not nephrotoxic or hepatotoxic. In fact, they may be organ-protective—especially for people with underlying metabolic issues. Myth #4: These Drugs Lead to Bone Loss The claim: “You'll get osteoporosis from losing too much weight!” The truth: While extreme weight loss can affect bone density, GLP-1s themselves do not cause bone loss, and may even have neutral or protective effects on bone. A 2022 study in Bone found no significant change in BMD (bone mineral density) in adults treated with semaglutide for obesity. While the SUSTAIN and PIONEER programs found no increased risk of fractures in semaglutide-treated patients versus placebo. Truly, concerns about bone loss are more relevant in extreme calorie restriction or eating disorders—not evidence-based GLP-1 treatment with appropriate nutrition. Myth #5: Everyone Gets Gastroparesis The claim: “These medications paralyze your stomach” The truth: GLP-1s slow gastric emptying, which is part of how they work—making you feel full longer. But this is dose-dependent and typically reversible. A 2023 FDA safety review found that true gastroparesis is extremely rare and resolves when the drug is stopped. Reality check: Nausea, early satiety, and mild bloating are common but manageable side effects. True, lasting gastroparesis is not typical, especially when doses are titrated gradually. Myth #6: GLP-1s Make Your Hair Fall Out The claim: “You'll lose a ton of hair—just like with crash diets” The truth: Hair shedding is not directly caused by GLP-1 medications. Instead, it's often a temporary, non-scarring condition called telogen effluvium, which can happen with any rapid weight loss, regardless of the method. A 2023 analysis from the American Academy of Dermatology emphasized that telogen effluvium is common with surgical or medical weight loss, especially if patients lose more than 10% of their body weight within a few months. In clinical trials like STEP and SURMOUNT, hair loss was not listed as a common side effect, but patient-reported data show it occurs occasionally—likely tied to nutritional stress, not the drug itself. So why does hair loss happen? We've talked about this before, but I don't want to leave this important information out.  Hair follicles are sensitive to internal stress. Rapid changes in caloric intake, nutrient levels (like iron, zinc, and biotin), or hormone balance can push hairs into the shedding phase. This is a delayed effect, often showing up 2–3 months after weight loss begins, and it typically resolves within 6–12 months. What helps is slower, sustained weight loss, prioritizing protein intake, supplementing iron, zinc, and biotin if deficient, and avoiding very low-calorie diets and over-restriction. Myth #6: GLP-1s Cause Dehydration It's a common myth that GLP-1 medications cause dehydration — but that's not exactly true. The medication itself doesn't directly dehydrate you. What can happen is that some people experience nausea, vomiting, or a reduced appetite early on, which can lead to drinking less water without realizing it. That's where the dehydration risk comes in. A good general rule for staying hydrated is to aim for half your body weight in ounces of water per day. So, for example, if you weigh 160 pounds, try to drink around 80 ounces daily — more if you're active or live in a hot climate. Electrolytes can also be really helpful, especially if you're feeling tired, dizzy, or crampy. I like LMNT packets — they're a clean option with no sugar and a good balance of sodium, magnesium, and potassium. The sodium in LMNT packets helps keep you hydrated by pulling water into your cells and helping your body retain the fluids it needs to function properly. Just one a day can make a big difference in how you feel. Myth #7: You Have to Stay on GLP-1s Forever or You'll Gain All the Weight Back The claim: “As soon as you stop taking it, all the weight comes back” The truth: Yes—some weight regain is likely after stopping GLP-1 medications. But that doesn't mean they're ineffective or that you're doomed to rebound completely. The same pattern happens after any type of weight loss intervention, whether it's a diet, surgery, or medication. The STEP 4 trial (Wilding et al., 2022) showed that participants who stopped semaglutide after 20 weeks regained an average of 6% of their weight loss over the next year. But it's important to note that they still weighed less than at baseline—and many continued to experience improvements in blood pressure, cholesterol, and insulin sensitivity. Similarly, in SURMOUNT-4, patients who stopped tirzepatide also regained weight, but less than they lost. So why does this weight gain happen? I feel like the answer to this is obvious, but I've found that it's not.  GLP-1s change your appetite and hunger cues. Once the medication is stopped, your body's baseline hunger signals return—and often with increased intensity, due to metabolic adaptation. But this isn't unique to GLP-1s. The same thing happens after crash diets, keto, intermittent fasting, or bariatric surgery if long-term changes aren't made. The real issue isn't the drug—it's the lack of a plan after the drug. To help make results sustainable, we need to use the medication as a tool, not a crutch. We should use it to help us lose weight and understand our hunger cues, while transitioning to a whole foods, protein based diet coupled with resistance training to help preserve and build muscle.  Just remember, if you're coming off a GLP-1 and want to keep the momentum going, the key is to approach it thoughtfully. Tapering slowly under medical supervision can help your body adjust and reduce the chances of weight regain. At the same time, this is a great moment to double down on the habits that helped you feel your best while on the medication. Think ongoing support—like working with a health coach, joining a support group, or even doing behavioral therapy—to help reinforce those long-term lifestyle changes. It's not just about what you stop; it's about what you keep doing that matters most. You don't necessarily have to stay on GLP-1s forever—but if you stop without a plan, some weight regain is very likely. Think of them like glasses: they help you see clearly while you build the habits to eventually navigate without them. For some, that may mean staying on a lower maintenance dose long-term—just like with blood pressure or cholesterol meds. What are my final thoughts? I want to be clear—GLP-1s aren't magic. But they are powerful tools when paired with education, support, and smart lifestyle changes.  Myths like ‘you'll go blind,' ‘you'll lose all your hair,' or ‘you'll be stuck on these meds forever' aren't just misleading and downright false—they discourage people from getting real help.  So if you're thinking about these medications, get informed, ask the hard questions, and make your decision based on science—not fear. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

Is high protein intake responsible for chronic kidney disease? Have you ever heard that ketogenic diets are harmful to your kidneys?These are just a few of the common kidney health myths debunked in this interview with Dr. Thomas Weimbs, who says that traditional views on what causes chronic kidney disease are “definitely not founded in science.”Dr. Thomas Weimbs, professor and vice chair at UC Santa Barbara, has spent decades studying chronic kidney disease (CKD). His recent research explores the impact of ketogenic interventions on kidney function, and the findings may surprise you. Rather than harming the kidneys, Dr. Weimbs is finding that keto can actually improve kidney function in people living with CKD.According to Dr. Weimbs, “Clearly, the number one cause of chronic kidney disease is not protein in excess—it's, of course, carbohydrates in excess and type 2 diabetes. Insulin resistance is causing chronic kidney disease.”In this episode, you'll learn:Why longstanding myths about protein and kidney function need to be re-examinedWhy misconceptions around keto and kidney health existHow ketogenic diets are showing promise for chronic kidney disease (including PKD)About results from randomized controlled trials and the 2-year Virta Health studyHow ketones may directly benefit kidney healthDr. Weimbs also shares insights from his lab's ongoing research—findings that challenge conventional thinking and call for a re-examination of how we understand and treat chronic kidney disease.Expert Featured:Dr. Thomas Weimbshttps://www.facebook.com/groups/256099897773551/https://santabarbaranutrients.com/CMEs Mentioned:Managing Major Mental Illness with Dietary Change: The New Science of Hopehttps://www.mycme.com/courses/managing-major-mental-illness-with-dietary-change-9616Brain Energy: The Metabolic Theory of Mental Illnesshttps://www.mycme.com/courses/brain-energy-the-metabolic-theory-of-mental-illness-9615Follow our channel for more information and education from Bret Scher, MD, FACC, including interviews with leading experts in Metabolic Psychiatry.Learn more about metabolic psychiatry and find helpful resources at https://metabolicmind.org/About us:Metabolic Mind is a non-profit initiative of Baszucki Group working to transform the study and treatment of mental disorders by exploring the connection between metabolism and brain health. We leverage the science of metabolic psychiatry and personal stories to offer education, community, and hope to people struggling with mental health challenges and those who care for them.Our channel is for informational purposes only. We are not providing individual or group medical or healthcare advice nor establishing a provider-patient relationship. Many of the interventions we discuss can have dramatic or potentially dangerous effects if done without proper supervision. Consult your healthcare provider before changing your lifestyle or medications.

What does effective kidney care look like in the primary care setting—and who's really involved beyond your GP? In this first of a special two-part series, host Dee Moore is joined by Dr. Kristin Veighey to explore the crucial yet often misunderstood role of primary care in managing chronic kidney disease (CKD).   This episode takes you beyond the GP, highlighting the power of the multidisciplinary team—including specialist nurses, pharmacists, health coaches, social prescribers, and mental health professionals—and how each plays a unique role in supporting kidney health.   Together, they discuss: • The definition and purpose of primary care vs. secondary care • Why CKD is often overlooked or mismanaged in primary care settings • The impact of legacy thinking, outdated guidelines, and unclear care pathways • How to navigate the system, understand who does what, and advocate for yourself • The importance of tracking your eGFR, blood pressure, and asking the right questions during health checks   This empowering episode is designed to help you take control of your kidney health journey by understanding your rights, responsibilities, and the full range of support available to you.  

Join us on this episode of Nothing But The Truth as we sit down with the remarkable Juliette Ashley Valle, Miss Florida 2023! Juliette shares her inspiring journey through the world of beauty pageants and beyond, revealing how she's leveraged her platform to advocate for critical causes. More about Juliette: ▸ Miss Florida 2023: Made history as the second Hispanic titleholder and the first Miss America contestant to deliver a bilingual onstage Q&A, placing in the Top 10 nationally. ▸ Advocate for Kidney Health & Women's Empowerment: A National Ambassador for Donate Life America and the National Kidney Foundation, she founded "Rise Up, Latinas!" – a nonprofit focused on Latina leadership and mentorship. ▸ Dynamic Background: A law student, aspiring reporter, and professional performer with a B.A. from the University of Miami and current studies at St. Thomas University College of Law and Harvard University. ▸ Award-Winning Talent: Recognized with multiple preliminary competition awards, she's also a verified recording artist who donates album proceeds to CKD charities.

In this episode of the Xtalks Life Science Podcast, Ayesha Rashid speaks with Laura Williams, MD, MPH, chief patient officer at Ardelyx, a company developing and commercializing first-in-class medicines for diseases like chronic kidney disease (CKD) and irritable bowel syndrome (IBS). Dr. Williams brings nearly 30 years of experience in clinical development, drug strategy and patient advocacy. With leadership roles across big pharma and biotech — including Abbott, Myovant and AMAG Pharmaceuticals — her impact is marked by eight FDA drug approvals and a relentless focus on improving patient outcomes. Before joining Ardelyx, Dr. Williams was SVP and head of clinical development and biostatistics at AMAG Pharmaceuticals, overseeing four investigational assets and two marketed products. She previously served as VP of clinical development at Myovant Sciences and spent 18 years at Abbott/AbbVie, where she led global clinical programs and managed the general medicine therapeutic area. Dr. Williams received a Bachelor of Science degree from Mississippi State University, a Doctor of Medicine degree from University of Iowa and a Master of Public Health degree in epidemiology from University of Washington, where she also completed a clinical fellowship in infectious diseases. She completed her Internal Medicine residency at University of Michigan, where she also served as Chief Resident and Junior Faculty. Tune in as Dr. Williams shares how her unique blend of scientific expertise and deep commitment to the patient voice drives innovation at Ardelyx. She discusses the evolving, up-and-coming role of chief patient officer, key lessons learned, the challenges of patient-centric drug development and what's ahead in addressing critical unmet medical needs. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

On this week's episode, Eric Schmidt, Brad Loncar, Tim Opler and Tess Cameron kick off with a discussion on the surgein biotech M&A, with 2025 almost matching 2024's deal count and surpassing it in value ($40B YTD vs $30B), highlighting recent deals like Merck's acquisition of Verona and AbbVie's purchase of Capstan. The group debateswhether this signals a true “M&A wave,” noting pharma's $150 billion of LOE approaching and reduced macro uncertainty could be driving deal flow. They alsonote a current competitive dynamic around commercial-stage assets. Shifting to policy, Trump's “Big Beautiful Bill” introduces key IRA exemptions for rare diseases and on tariffs, the co-hosts note the market's quiet reaction andwonder if investors are becoming desensitized to D.C. headlines. As M&A steadies and drug launches hold strong despite pricing pressure, some stability seems to be on the way. On the regulatory front, the group praises the FDA'simproved communication under new leadership, citing their strong online presence and experience with media. Despite the FDA's recent rejection of Capricor's cell therapy for DMD, optimism remains about the therapy's potential. Despite the improved communication discussed earlier, questionsabout the FDA's transparency arise following the agency's issuance of CRLs to be more transparent; it remains uncertain if this trend will continue. Conversation shifts to data, overviewing KalVista's approval of Ekterly, thefirst oral calcineurin inhibitor approved for hereditary angioedema attacks and ProKidney's cell therapy that showed improved eGFR slope in CKD patients in aPhase 2 trial, skyrocketing shares. The episode closes with a conversation on obesity trends. *This episode aired on July 11, 2025. 

Episode 198: Fatigue.  Future doctors Redden and Ibrahim discuss with Dr. Arreaza the different causes of fatigue, including physical and mental illnesses. Dr. Arreaza describes the steps to evaluate fatigue. Some common misconceptions are explained, such as vitamin D deficiency and “chronic Lyme disease”. Written by Michael Ibrahim, MSIV, and Jordan Redden, MSIV, Ross University School of Medicine. Edits and comments by Hector Arreaza, MDYou are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Dr. Arreaza: Today is a great day to talk about fatigue. It is one of the most common and most complex complaints we see in primary care. It involves physical, mental, and emotional health. So today, we're walking through a case, breaking down causes, red flags, and how to work it up without ordering the entire lab catalog.Michael:Case: This is a 34-year-old female who comes in saying, "I've been feeling drained for the past 3 months." She says she's been sleeping 8 hours a night but still wakes up tired. No recent illnesses, no weight loss, fever, or night sweats. She denies depression or anxiety but does report a lot of work stress and taking care of her two little ones at home. She drinks 2 cups of coffee a day, doesn't drink alcohol, and doesn't use drugs. No medications, just a multivitamin. Regular menstrual cycles—but she's noticed they've been heavier recently.Jordan:Fatigue is a persistent sense of exhaustion that isn't relieved by rest. It's different from sleepiness or muscle weakness.Classification based on timeline:    •   Acute fatigue: less than 1 month    •   Subacute: 1 to 6 months    •   Chronic: more than 6 monthsThis patient's case is subacute—going on 3 months now.Dr. Arreaza:And we can think about fatigue in types:    •   Physical fatigue: like muscle tiredness after activity    •   Mental fatigue: trouble concentrating or thinking clearly (physical + mental when you are a medical student or resident)    •    Pathological fatigue: which isn't proportional to effort and doesn't get better with restAnd of course, there's chronic fatigue syndrome, also called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), which is a diagnosis of exclusion after 6 months of disabling fatigue with other symptoms.Michael:The differential is massive. So, we can also group it by systems.Jordan:Let's run through the big ones.Endocrine / Metabolic Causes    • Hypothyroidism: A classic cause of fatigue. Often associated with cold intolerance, weight gain, dry skin, and constipation. May be subtle and underdiagnosed, especially in women.    • Diabetes Mellitus: Both hyperglycemia and hypoglycemia can cause fatigue. Look for polyuria, polydipsia, weight loss, or blurry vision in undiagnosed diabetes.    • Adrenal Insufficiency: Think of this when fatigue is paired with hypotension, weight loss, salt craving, or hyperpigmentation. Can be primary (Addison's) or secondary (e.g., due to long-term steroid use).Michael: Hematologic Causes    • Anemia (especially iron deficiency): Very common, especially in menstruating women. Look for fatigue with pallor, shortness of breath on exertion, and sometimes pica (craving non-food items).     • Vitamin B12 or Folate Deficiency: B12 deficiency may present with fatigue plus neurologic symptoms like numbness, tingling, or gait issues. Folate deficiency tends to present with megaloblastic anemia and fatigue.    • Anemia of Chronic Disease: Seen in patients with chronic inflammatory conditions like RA, infections, or CKD. Typically mild, normocytic, and improves when the underlying disease is treated.Michael: Psychiatric Causes    • Depression: A major driver of fatigue, often underreported. May include anhedonia, sleep disturbance, appetite changes, or guilt. Sometimes presents with only somatic complaints.    • Anxiety Disorders: Mental fatigue, poor sleep quality, and hypervigilance can leave patients feeling constantly drained.    • Burnout Syndrome: Especially common in caregivers, healthcare workers, and educators. Emotional exhaustion, depersonalization, and reduced personal accomplishment are key features.Jordan: Infectious Causes    • Epstein-Barr Virus (EBV):Mononucleosis is a well-known cause of fatigue, sometimes lasting weeks. May also have sore throat, lymphadenopathy, and splenomegaly.    • HIV:Consider it in high-risk individuals. Fatigue can be an early sign, along with weight loss, recurrent infections, or night sweats.    • Hepatitis (B or C):Can present with chronic fatigue, especially if liver enzymes are elevated. Screen at-risk individuals.    • Post-viral Syndromes / Long COVID:Fatigue that lingers for weeks or months after viral infection. Often, it includes brain fog, muscle aches, and post-exertional malaise.Important: Chronic Lyme disease is a controversial term without a consistent clinical definition and is often used to describe patients with persistent, nonspecific symptoms not supported by objective evidence of Lyme infection. Leading medical organizations reject the term and instead recognize "post-treatment Lyme disease syndrome" (PTLDS) for persistent symptoms following confirmed, treated Lyme disease, emphasizing that prolonged antibiotic therapy is not effective. Research shows no benefit—and potential harm—from extended antibiotic use, and patients with unexplained chronic symptoms should be thoroughly evaluated for other possible diagnoses.Michael: Cardiopulmonary Causes    •   Congestive Heart Failure (CHF): Fatigue from poor perfusion and low cardiac output. Often comes with dyspnea on exertion, edema, and orthopnea.    •   Chronic Obstructive Pulmonary Disease (COPD): Look for a smoking history, chronic cough, and fatigue from hypoxia or the work of breathing.    •   Obstructive Sleep Apnea (OSA): Daytime fatigue despite adequate hours of sleep. Patients may snore, gasp, or report morning headaches. High suspicion in obese or hypertensive patients.Jordan:Autoimmune / Inflammatory Causes    •   Systemic Lupus Erythematosus (SLE): Fatigue is often an early symptom. May also see rash, arthritis, photosensitivity, or renal involvement.    •   Rheumatoid Arthritis (RA): Fatigue from systemic inflammation. Morning stiffness, joint pain, and elevated inflammatory markers point to RA.    •   Fibromyalgia: A chronic pain syndrome with widespread tenderness, fatigue, nonrestorative sleep, and sometimes cognitive complaints ("fibro fog").Cancer / Malignancy    •   Leukemia, lymphoma, or solid tumors: Fatigue can be the first symptom, often accompanied by weight loss, night sweats, or unexplained fevers. Consider when no other cause is evident.Michael:Medications:Common culprits include:    ◦   Beta-blockers: Can slow heart rate too much.    ◦   Antihistamines: Sedating H1 blockers like diphenhydramine.    ◦   Sedatives or sleep aids: Can cause grogginess and daytime sedation.    •   Substance Withdrawal: Fatigue can be seen in withdrawal from alcohol, opioids, or stimulants. Caffeine withdrawal, though mild, can also contribute.Dr. Arreaza:Whenever we evaluate fatigue, we need to keep an eye out for red flags. These should raise suspicion for something more serious:    •   Unintentional weight loss    •   Night sweats    •   Persistent fever    •   Neurologic symptoms    •   Lymphadenopathy    •   Jaundice    •   Palpitations or chest painThis patient doesn't have these—but that doesn't mean we stop here.Dr. Arreaza:Those are a lot of causes, we can evaluate fatigue following 7 steps:Characterize the fatigue.Look for organic illness.Evaluate medications and substances.Perform psychiatric screening.Ask questions about quantity and quality of sleep.Physical examination.Undertake investigations.So, students, do we send the whole lab panel?Michael:Not necessarily. Labs should be guided by history and physical. But here's a good initial panel:    •   CBC: To check for anemia or infection    • TSH: Screen for hypothyroidism    • CMP: Look at electrolytes, kidney, and liver function    • Ferritin and iron studies    • B12, folate    • ESR/CRP for inflammation (not specific)    • HbA1c if diabetes is on the radarJordan:And if needed, consider:    • HIV, EBV, hepatitis panel    • ANA, RF    • Cortisol or ACTH stimulation testImaging? Now that's rare—unless there are specific signs. Like chest X-ray for possible cancer or TB, or sleep study if you suspect OSA.Dr. Arreaza:Unaddressed fatigue isn't just inconvenient. It can impact on quality of life, affect job performance, lead to mood disorders, delay diagnosis of serious illness, increase risk of accidents—especially driving. So, don't ignore your patients with fatigue!Jordan:And some people—like women, caregivers, or shift workers—are especially at risk.Michael:The cornerstone of treatment is addressing the underlying cause.Jordan:If it's iron-deficiency anemia—treat it. If it's depression—get mental health involved. But there's also: Lifestyle Support: Better sleep hygiene, light physical activity, mindfulness or CBT for stress, balanced nutrition—especially iron and protein, limit caffeine and alcoholDr. Arreaza:Sometimes medications help—but rarely. And for chronic fatigue syndrome, the current best strategies are graded exercise therapy and CBT, along with managing specific symptoms. Beta-alanine has potential to modestly improve muscular endurance and reduce fatigue in older adults, but more high-quality research is needed.SSRI: fluoxetine and sertraline. Iron supplements: Even without anemia, but low ferritin [Anecdote about low ferritin patient]Jordan:This case reminds us to take fatigue seriously. In her case, it may be multifactorial—work stress, caregiving burden, and possibly iron-deficiency anemia. So, how would we wrap up this conversation, Michael?Michael:We don't need to order everything under the sun. A focused history and exam, targeted labs, and being alert to red flags can guide us.Jordan:And don't forget the basics—sleep, stress, and nutrition. These are just as powerful as any prescription.Dr. Arreaza:We hope today's episode on fatigue has given you a clear framework and some practical tips. If you enjoyed this episode, share it and subscribe for more evidence-based medicine!Jordan:Take care—and get some rest~___________________________Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:DynaMed. (2023). Fatigue in adults. EBSCO Information Services. https://www.dynamed.com (Access requires subscription)Jason, L. A., Sunnquist, M., Brown, A., Newton, J. L., Strand, E. B., & Vernon, S. D. (2015). Chronic fatigue syndrome versus systemic exertion intolerance disease. Fatigue: Biomedicine, Health & Behavior, 3(3), 127–141. https://doi.org/10.1080/21641846.2015.1051291Kroenke, K., & Mangelsdorff, A. D. (1989). Common symptoms in ambulatory care: Incidence, evaluation, therapy, and outcome. The American Journal of Medicine, 86(3), 262–266. https://doi.org/10.1016/0002-9343(89)90293-3National Institute for Health and Care Excellence. (2021). Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: Diagnosis and management (NICE Guideline No. NG206). https://www.nice.org.uk/guidance/ng206UpToDate. (n.d.). Approach to the adult patient with fatigue. Wolters Kluwer. https://www.uptodate.com (Access requires subscription)Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

Join us for an inspiring episode of the Diary of a Kidney Warrior Podcast as we sit down with Ravi—a fellow Kidney Warrior whose story is one of courage, connection, and unshakeable will. From his unexpected diagnosis of Chronic Kidney Disease (CKD) to life on dialysis, Ravi opens up about the challenges and triumphs that have shaped his journey.   What began as a routine post-holiday health concern quickly became a life-altering revelation. Ravi walks us through the early warning signs, the shock of diagnosis, and the complexities of seeking care amid a global pandemic. As dialysis buddies turned friends, Ravi and our host share a powerful camaraderie that highlights the strength found in community.   In this candid conversation, Ravi speaks openly about the physical, mental, and emotional toll of CKD—detailing side effects, collapsing from poor health, and the resilience needed to push through. Balancing a demanding career in IT, he reveals how he copes with the daily realities of dialysis and the hope of an eventual transplant.   Whether you're newly diagnosed or supporting someone with CKD, Ravi's insights offer encouragement, practical advice, and heartfelt wisdom. He champions the importance of early detection, mental well-being, and finding purpose amidst the struggle.  

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for June 30-July 6, 2025: Sebetralstat FDA-Approved as First Oral, On-Demand for Hereditary Angioedema The FDA approved sebetralstat (Ekterly) on July 7, 2025, as the first oral, on-demand treatment for hereditary angioedema attacks in patients aged 12 and older, backed by phase 3 KONFIDENT trial data. Rilparencel Improves eGFR Slope in Phase 2 CKD, Diabetes REGEN-007 Trial Rilparencel significantly slowed kidney function decline in CKD patients with diabetes in the REGEN-007 trial, showing dose-responsive eGFR slope improvements after two injections per kidney. J&J Submits sNDA to FDA for Lumateperone (CAPLYTA) to Prevent Schizophrenia Relapse J&J filed a supplemental NDA for lumateperone after phase 3 data showed a 63% reduction in schizophrenia relapse risk compared to placebo. FDA Publishes CRLs for Past Drug, Biological Product Applications The FDA publicly released over 200 Complete Response Letters from 2020–2024 to increase regulatory transparency and help accelerate future drug approvals. FDA Grants TSND-201 Breakthrough Therapy Designation for PTSD TSND-201 (methylone) received Breakthrough Therapy designation for PTSD on July 10, 2025, offering a potential rapid-acting alternative to SSRIs, which can take up to 12 weeks for full effect.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-latest-data-in-ckd-progression-10197SummaryEmerging evidence highlights the potential of GLP-1 receptor agonists (GLP-1 RAs) to slow CKD progression and reduce cardiovascular and kidney-related mortality in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD). Yet, despite updated guidelines, these therapies remain underused. This program will explore the latest clinical data supporting the role of GLP-1 RAs in risk mitigation and provide practical strategies for implementing guideline-based treatment to reduce cardio-renal risk and improve outcomes in patients with T2D and CKD.This podcast was recorded and is being used with permission of the presenters.Learning ObjectivesAt the conclusion of this activity, participants should be better able to:Discuss emerging data on GLP-1 RA therapy for CKD progression in T2DImplement guideline-based care to minimize CV risk and CKD progressionThis activity is accredited for CME/CE CreditThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.The National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).For additional information about the accreditation of this program, please contact NACE at info@naceonline.com.Summary of Individual DisclosuresPlease review faculty and planner disclosures here.Disclosure of Commercial SupportThis activity is supported by an educational grant from Novo Nordisk.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Chronic kidney disease, or CKD, is the most common cause of death in senior…

Chronic kidney disease, or CKD, is the most common cause of death in senior cats. Unfortunately, it's usually not diagnosed until symptoms are advanced. But when it's caught early, targeted...

From Diagnosis to Artivism: Steve's Extraordinary Kidney Warrior Journey   In this powerful episode of Diary of a Kidney Warrior Podcast, Dee sits down with Steve — a passionate creative whose life was forever changed by an unexpected diagnosis of chronic kidney disease (CKD).   At just 30% kidney function and no warning signs, Steve's diagnosis came as a shock. He takes us through the moment his world shifted: a sudden phone call that catapulted him into the reality of dialysis. What follows is a deeply human story of resilience — navigating peritoneal dialysis, transitioning to haemodialysis, and balancing the demands of treatment with the challenges of self-employment in web design.   But this is no ordinary journey.   Steve opens up about receiving his first kidney transplant, the hope it brought, and the heartbreak when things took a turn — sending him back to dialysis and confronting the fragility of life with CKD. Throughout it all, he emphasises the critical importance of self-advocacy in the healthcare system, offering insights that every patient or caregiver needs to hear.   What truly sets Steve apart is how he channels pain into purpose. Through painting, he found not just therapy, but a voice — using art as activism to raise awareness about kidney disease. His work, featured in exhibitions supporting Kidney Care UK, is raw, reflective, and at times, joyfully humorous — a visual diary of his fight and spirit.   The episode builds to a beautiful full-circle moment as Steve shares the emotional story of receiving a second transplant — this time from his brother — and the freedom that followed. His message is clear: creativity can be healing, storytelling is powerful, and no one walking this journey is alone.   If you're living with CKD, supporting a loved one, or simply need a reminder of the strength of the human spirit, this episode will leave you inspired, informed, and deeply moved.   Follow Diary of a Kidney Warrior:  

In this episode of the Yumlish podcast, Shireen Abdullah speaks with Dr. Anshu Chaturvedi—a renal clinical dietitian with over 12 years of experience—and discusses how personalized nutrition can transform chronic disease management. Sharing both professional insights and personal experience with IBS, she explains how intermittent fasting and thoughtful meal sequencing can improve metabolic health and reduce blood sugar levels. Dr. Chaturvedi emphasizes that food is not “good” or “bad,” but should be tailored to individual needs. She provides practical strategies for portion control, timing and plant-based eating while also revealing her own daily routine for managing wellness. This episode is full of accessible, culturally inclusive guidance for anyone looking to eat smarter and live healthier.Dr. Anshu Chaturvedi is a highly experienced Renal Clinical Dietitian with a Ph.D. in Renal nutrition, over 12 years of expertise in clinical nutrition, specializing in the management of various lifestyle disorders including diabetes mellitus, chronic kidney disease (CKD) and related conditions. She focuses on the development of personalized nutritional interventions that enhance the health outcomes of patients “Every food is good—until and unless your body is accepting that food. It's not about good or bad food. It's about what works for you and how you care for your health with intention.” Question of the Day:Have you made any changes to your diet recently? What do those changes look like?On This Episode You Will Learn:How intermittent fasting can be tailored to different body types and health needs.The importance of meal sequence (fiber → protein → carbs) for better blood sugar control.Why inflammation and poor metabolic health are core contributors to diabetes.How plant-based diets can reduce inflammation and support diabetes management.Practical tips for portion control and timing your meals for long-term health benefits.Connect with Yumlish!Yumlish Website: YumlishYumlish on Instagram: @yumlish_Yumlish on Facebook: YumlishYumlish on Twitter: @yumlish_Connect with Dr. Chaturvedi!Instagram URL: https://www.instagram.com/anshu_chaturvedii?igsh=MW00eG5rMmVxazBmMA==Facebook URL: https://www.facebook.com/share/18s6KR9T9t/LinkedIn URL: https://www.linkedin.com/in/anshu-chaturvedi-1027a796?utm_source=share&utm_campaign=share_via&utm_content=profile&utm_medium=android_app

In this episode, we review the pharmacology, indications, adverse effects, monitoring, and unique drug characteristics of angiotensin receptor blockers (ARBs).  Key Concepts ARBs are equally efficacious as ACE inhibitors when used for hypertension, heart failure with reduced ejection fraction (HFrEF), chronic kidney disease (CKD) with proteinuria, and post-MI care. Some limited evidence suggests that they might be better in reducing albuminuria in patients with diabetes. ARBs are generally better tolerated than ACEi due to a lower risk of angioedema and dry cough.  While most ARBs are comparable to each other, small differences exists regarding hepatic metabolism (CYP metabolism for losartan, telmisartan, and azilsartan), degree of blood pressure lowering (generally better with azilsartan, olmesartan, valsartan, and candesartan), and additional pharmacological effects (telmisartan with PPAR-Y agonism, losartan with uricosuric effect). ARBs are contraindicated in pregnancy, those with bilateral renal artery stenosis, and those with previous angioedema to ARBs. The most common adverse effects include hypotension and hyperkalemia, but in rare cases acute renal impairment can also occur. Baseline serum creatinine and potassium should be monitored in patients taking ARBs. After initiation or dose adjustment, blood pressure, serum creatinine, and potassium should be repeated in 1-2 weeks. Signs and symptoms of hypotension as well as angioedema should be monitored throughout the treatment period.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Dr. Reaves and Dr. Sarnak on "Benefits and risks of intensive blood pressure control in CKD patients: what does the current evidence tell us?" from nephSAP Vol 24, No 2.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Dr. Reaves and Dr. Sarnak on "Benefits and risks of intensive blood pressure control in CKD patients: what does the current evidence tell us?" from nephSAP Vol 24, No 2.

In this powerful and deeply personal episode of Diary of a Kidney Warrior Podcast, we meet Christy—an extraordinary kidney warrior whose story of resilience will inspire anyone facing life's toughest battles.   Christy takes us back to 2006, when a life-threatening crisis landed her in a coma, leading to kidney failure caused by septicaemia and peritonitis. What followed was nearly two decades of living with chronic kidney disease (CKD)—a journey marked by dialysis as a young adult, the heartbreak of a failed transplant, and the constant balancing act of managing additional health complications.   But Christy's story doesn't stop at survival. She shares how she transformed her adversity into advocacy, building a vibrant online community and launching her own podcast, Chronically Christy, to connect with and uplift other kidney patients.   With honesty and wisdom, Christy speaks about:

Listener feedback on cardiac sarcoidosis, SA node ablation, surgical AF ablation, chronic kidney disease protection, and recruiting for clinical trials are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback EHJ paper Mathijssen et al https://doi.org/10.1093/eurheartj/ehaf338 Nordenswan et al https://www.ahajournals.org/doi/full/10.1161/CIRCEP.117.006145#tab-contributors II IST HR Case Reports https://doi.org/10.1016/j.hrcr.2025.05.017 Lakkireddy et al https://doi.org/10.1016/j.hrthm.2021.07.010 III Survival After Surgical AF ablation during CABG McClure et al https://doi.org/10.1093/europace/eux336 Schaffer et al https://doi.org/10.1016/j.athoracsur.2025.03.044 IV Finerenone with Empagliflozin in CKD and DM The Confidence Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2410659 V Recruiting for Important Trials and the Stature of EP as a Profession Two UK Cardiology Trials Struggle to Recruit Patients https://www.medscape.com/viewarticle/two-uk-cardiology-trials-struggle-recruit-patients-2025a1000ffs CRAFT HF https://clinicaltrials.gov/study/NCT06505798 BRITISH https://doi.org/10.1016/j.ahj.2023.09.008 PROFID https://profid-project.eu/profid-ehra-trial/ You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

CME credits: 0.25 Valid until: 06-06-2026 Claim your CME credit at https://reachmd.com/programs/cme/nonsteroidal-mra-sglt2i-in-people-with-ckd-t2d-current-evidence-and-rationale-for-combination-therapy/29909/ Can combining a nonsteroidal MRA and an SGLT2 inhibitor unlock new clinical potential for patients with type 2 diabetes and chronic kidney disease (CKD)? In this expert discussion, Dr. Jennifer Green and Dr. Hiddo Heerspink review the latest findings from the CONFIDENCE trial, which demonstrated a significant additive reduction in albuminuria—an important surrogate marker for kidney and cardiovascular risk—when finerenone and empagliflozin are used together. They explore the clinical rationale behind combination therapy, address persistent challenges in CKD detection, and consider the practical implications for implementing these therapies in high-risk populations.=

Why You Should Listen:  In this episode, you will learn about chronic kidney disease and how to address the Kidneydemic with Renology. About My Guest: My guest for this episode is Dr. Robin Rose.  Robin Rose, MD began a journey into holistic healing in her teens in the mid-sixties beginning with nutrition and botanical medicine and yoga and meditation.  Over the years her journey included time living in India and working with both village doctors and healers.  She became a health food chef and inspired many to change their habits.  Before long she was enrolled in an RN program and then a family nurse practitioner program.  Aware that the education wasn't complete, she attended University of Arizona College of Medicine; while also serving as a medical student board member for the American Holistic Medical Association.  During residency, she continued learning Chinese medicine, acupuncture, osteopathy, energy medicine, and herbal medicine.  Her main practice was in Ashland, Oregon where she served a community eager to integrate many healing modalities into the conventional setting, including innovative care in the hospital.  In the past decade after her own alarming health challenges with kidney cancer and advanced kidney disease, she became agile in regenerative medical approaches to kidney care.  She created a new specialty called Renology; a new concept of "Kidney Success" not Kidney Failure.  When she discovered peptides and especially bioregulator peptides, she led the brigade to new heights of seeing success in a field that had not embraced this kind of care.  Her recent book "Renology Peptides" is a nearly 800 page text on how to achieve this renewal of health.  Her current intention is to raise awareness of the role of kidney in wellbeing and how we can all celebrate this success.  Key Takeaways: What is the purpose of the kidneys? What symptoms are observed in chronic kidney disease? Is kidney disease a catabolic process? Is kidney disease genetic or epigenetic? What are the stages of kidney disease? What are the best tests and lab markers? What might elevations or phosphorous or potassium suggest? What is the kidney-gut axis? What is the role of endothelial health in kidney disease? What role do the mitochondria play?  How do infections and environmental toxicants contribute to kidney disease? What is the role of oxalates in kidney health? How might carbon dioxide guide treatment? Does cellular senescence play a role? What is the connection between the kidneys and the teeth? How do the limbic system and mental/emotional health impact the kidneys? What treatment intervention warrant exploration? Where do dialysis and transplantation come into the discussion? What role might peptides and peptide bioregulators play? Connect With My Guest:  RenologyIsKidneySuccess.com Interview Date: May 21, 2025 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode217. Additional Information: To learn more, visit https://BetterHealthGuy.com. Follow Me on Social Media: Facebook - https://facebook.com/betterhealthguy Instagram - https://instagram.com/betterhealthguy X - https://twitter.com/betterhealthguy TikTok - https://tiktok.com/@betterhealthguy Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

Why You Should Listen:  In this episode, you will learn about chronic kidney disease and how to address the Kidneydemic with Renology. About My Guest: My guest for this episode is Dr. Robin Rose.  Robin Rose, MD began a journey into holistic healing in her teens in the mid-sixties beginning with nutrition and botanical medicine and yoga and meditation.  Over the years her journey included time living in India and working with both village doctors and healers.  She became a health food chef and inspired many to change their habits.  Before long she was enrolled in an RN program and then a family nurse practitioner program.  Aware that the education wasn't complete, she attended University of Arizona College of Medicine; while also serving as a medical student board member for the American Holistic Medical Association.  During residency, she continued learning Chinese medicine, acupuncture, osteopathy, energy medicine, and herbal medicine.  Her main practice was in Ashland, Oregon where she served a community eager to integrate many healing modalities into the conventional setting, including innovative care in the hospital.  In the past decade after her own alarming health challenges with kidney cancer and advanced kidney disease, she became agile in regenerative medical approaches to kidney care.  She created a new specialty called Renology; a new concept of "Kidney Success" not Kidney Failure.  When she discovered peptides and especially bioregulator peptides, she led the brigade to new heights of seeing success in a field that had not embraced this kind of care.  Her recent book "Renology Peptides" is a nearly 800 page text on how to achieve this renewal of health.  Her current intention is to raise awareness of the role of kidney in wellbeing and how we can all celebrate this success.  Key Takeaways: What is the purpose of the kidneys? What symptoms are observed in chronic kidney disease? Is kidney disease a catabolic process? Is kidney disease genetic or epigenetic? What are the stages of kidney disease? What are the best tests and lab markers? What might elevations or phosphorous or potassium suggest? What is the kidney-gut axis? What is the role of endothelial health in kidney disease? What role do the mitochondria play?  How do infections and environmental toxicants contribute to kidney disease? What is the role of oxalates in kidney health? How might carbon dioxide guide treatment? Does cellular senescence play a role? What is the connection between the kidneys and the teeth? How do the limbic system and mental/emotional health impact the kidneys? What treatment intervention warrant exploration? Where do dialysis and transplantation come into the discussion? What role might peptides and peptide bioregulators play? Connect With My Guest:  RenologyIsKidneySuccess.com Interview Date: May 21, 2025 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode218. Additional Information: To learn more, visit https://BetterHealthGuy.com. Follow Me on Social Media: Facebook - https://facebook.com/betterhealthguy Instagram - https://instagram.com/betterhealthguy X - https://twitter.com/betterhealthguy TikTok - https://tiktok.com/@betterhealthguy Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

Struggling to balance work and kidney disease? You're not alone — and this episode is your essential guide to thriving professionally and medically. We're joined by Dr. Jacquie, a leading expert in occupational health, to explore the critical intersection of employment, rights, and wellbeing for people living with chronic kidney disease (CKD).  

New Steroid Rules for Lupus - Dr. Michelle Petri Management of CKD in Lupus Nephritis - Dr. HJ Anders HCQ Levels and Adherence - Dr. Nathalie Costedoat-Chalumeau Lupus Nephritis Guidelines - a debate - Drs. Michelle Petri and Maria Dall'Era Nephrologists Approach to Lupus Nephritis - Dr. Brad Rovin Voclosporin and Steroids in Lupus Nephritis - Dr. Jack Cush

Targeting the cardiovascular (CV)-kidney-metabolic (CKM) axis may improve outcomes in patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) by addressing interconnected metabolic, kidney, and CV risks.   Credit available for this activity expires: 5/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002559?ecd=bdc_podcast_libsyn_mscpedu

Health care executive and patient advocate Aja Best discusses her article, "How early CKD diagnosis can save lives: a transplant survivor's journey." She shares her harrowing personal experience with a delayed diagnosis of IgA nephropathy during pregnancy, which led to a challenging path through dialysis and ultimately to a life-saving kidney transplant. Aja highlights the often-silent progression of chronic kidney disease (CKD), a growing global health crisis, and points to critical gaps in the health care system that prevent timely intervention. The conversation explores the importance of early screening, proactive and coordinated care, the potential of technology and predictive analytics to improve patient outcomes, and the power of patient advocacy. Aja passionately calls for systemic changes and greater awareness to ensure others don't face the same missed opportunities she did. The key takeaway is: Early CKD detection through routine screening and a more integrated, patient-centered health care approach can significantly alter disease progression, improve lives, and reduce the burden of this widespread condition. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

Modern medicine has made significant strides in managing chronic diseases, yet many elderly patients with multiple conditions continue to deteriorate under standard care. Conventional therapies often overlook the root causes of chronic degeneration, such as oxidative stress, mitochondrial dysfunction, toxin accumulation, and nutritional deficiencies. IntegrativeOrthomolecular Medicine (IOM) offers a solution-oriented framework that emphasizes restoring biochemical balance through therapeutic nutrition, detoxification, metabolic support, and lifestyle interventions. This case study illustrates the practical application and impressive results of an IOM protocol in an elderly woman with T2DM, CKD with renal insufficiency, Parkinsonism, and recurrent infections.In this episode George discusses the case study of a 94 year old woman who made significant improvements using Orthromolecular nutrition. www.georgebatista.com

In this podcast, Dr. Valentin Fuster reviews findings from the SUMMIT trial, which examined how tirzepatide impacts patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and chronic kidney disease (CKD). The study revealed that while tirzepatide improved cardiovascular outcomes and slightly boosted kidney function, the benefits in CKD patients may stem from mechanisms beyond glomerular filtration alone.

During this episode a panel of experts discuss the patient journey through the interpretation and application of safety and efficacy data to establish and maintain protocols designed to address optimal VTE treatment pathways. Claim CE and MOC Credit at bit.ly/VTEPJ6 

In this episode, Lori talks with nephrologist Dr. Arun Malhotra about what inspired him to pursue nephrology and dives into an important discussion about the connection between chronic kidney disease (CKD) and high potassium, also known as hyperkalemia. They cover symptoms to watch for, the role of diet, how to manage potassium levels, and the importance of working closely with healthcare providers.

The interplay between cardiovascular disease, chronic kidney disease (CKD), and diabetes is complex and often underappreciated.   Credit available for this activity expires: 4/30/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002395?ecd=bdc_podcast_libsyn_mscpedu

In this powerful episode of Diary of a Kidney Warrior Podcast, host Dee Moore is joined by Nick Palmer, who shares his extraordinary journey of living with chronic kidney disease (CKD) and focal segmental glomerulosclerosis (FSGS). Diagnosed at just 19 years old, Nick opens up about navigating the complex realities of kidney disease as a young adult—balancing university, a demanding career, and the emotional toll of a condition that would require multiple transplants and ongoing dialysis.   With unflinching honesty, Nick reflects on his decision to decline a third kidney transplant and instead embrace home nocturnal dialysis—a choice that profoundly improved his quality of life, restored his sense of independence, and helped him reclaim control of his health. He discusses the impact of this decision on his mental well-being, family life, and career, and how it ultimately allowed him to thrive in ways he never expected.   Nick's story challenges traditional narratives around kidney treatment, shining a light on the importance of patient choice, education, and mental health advocacy in chronic illness care. This episode is a must-listen for anyone navigating kidney disease, healthcare professionals, or anyone seeking inspiration from a story of resilience and informed self-advocacy.   Key topics include: Living with FSGS and the impact of early diagnosis The emotional and physical toll of dialysis in early adulthood The recurrence of FSGS post-transplant Choosing nocturnal dialysis and the profound benefits for quality of life Mental health, self-advocacy, and redefining what it means to live fully with CKD   Follow Diary of a Kidney Warrior:  

Did you know that patient registries play a vital role in improving kidney disease treatment and outcomes? In this episode, we're diving into the KidneyCARE Study—a patient registry that uses real-world data to better care for people with kidney disease. We sat down with experts as they explained what a patient registry is and why people with kidney disease may want to join the KidneyCARE Study. In today's episode we heard from:    Kerry K. Willis PhD- Dr Willis is the Chief Scientific Officer of the National Kidney Foundation (NKF). Since joining NKF in 1998, her major focus has been on the analysis and application of clinical evidence to improve care and outcomes for people living with kidney disease. She oversees all NKF-sponsored research and professional education programs, including the Spring Clinical Meetings; population health programs that facilitate health system and practice engagement around CKD as a quality improvement target; the Kidney Disease Outcomes Quality Initiative (KDOQI) clinical practice guidelines; KDOQI quality measurement initiative; and four peer-reviewed journals devoted to chronic kidney disease. She led the development of and currently manages the Kidney CARE (Community Access to Research Equity) Study, the first national CKD patient registry to combine patient-reported data with clinical data from electronic health records.     Rachel Claudin, BS, CCLS- Rachel Claudin is the Patient-Centered Research Director at the National Kidney Foundation (NKF). Her main work for the past three years has been focused on the advancement of the KidneyCARE Study. As a person living with Lupus Nephritis, she is excited for the patient-entered data collected by the Study to increase and improve kidney care research. Previous to the NKF, Rachel worked in hospital and hospice settings advocating for patients utilizing the shared decision-making model of healthcare. Cari Maxwell- Cari has lived with Polycystic Kidney Disease (ADPKD) since 1989, and her personal experience, along with the experiences of her father and two siblings, fuels her advocacy for advancements in PKD treatment. She participated in the Tolvaptan Reprise trial, which led to the first-ever FDA-approved treatment for ADPKD—a treatment she continues to benefit from today. As a member of the NKF Kidney Advocacy Committee, Cari is passionate about promoting patient education, early detection, and scientific progress through patient-centered clinical research. She is dedicated to ensuring that others have access to life-changing treatments and are empowered to advocate for their health through proactive care. Cari currently works in health care cost containment strategies, where she applies her expertise to enhance patient access and outcomes. Sandy Gilbert PhD- Sandy Gilbert is the Senior Director of Patient Outcomes Research at the National Kidney Foundation (NKF), where she manages the KidneyCARE (Community Access to Research Equity)™ Study. Since joining NKF in 2024, her focus has been on developing and overseeing this pioneering national kidney disease patient registry, the first to integrate patient-reported data with clinical data from electronic health records. The goal of the Registry is to generate critical insights into disease progression, treatment outcomes, and health disparities, in support of NKF's mission to improve kidney health and drive innovation in kidney research and healthcare. Sandy works closely with teams of researchers and health system partners to expand the study's reach and ensure that it reflects the needs of diverse patient populations, including those from underserved communities. Additional Resources: KidneyCare Study Information Contact Information: Call: 212.889.2210 ext.134 M-F 10am-4pm CT  Email: kidneycarestudy@kidney.org   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Tune in to The Heart of Innovation this week as we share an incredible story of a young woman who helped save her grandfather's life and now is trying to save others through organ donation advocacy. Since it's National Kidney Month, Emmy Award-winning journalist Kym McNicholas and Dr. John Phillips interview Danica Almazan, RN and Miss Marin County 2025, whose family's courageous fight against kidney disease sparked a powerful mission of hope. You might wonder why we are talking about kidney disease on a show about cardiovascular and vascular health. Kidney disease, especially in advanced stages can lead to peripheral artery disease, which is poor circulation in mainly the legs, and lead to amputation. Many of the peripheral artery disease (PAD) patients both Kym and Dr. John support have CKD and ESRD, some of which are also in need of a kidney transplant. They want to get the word out there on the importance of kidney health as well as raise awareness that all kidney disease patients should be checked for peripheral artery disease and to find a doctor who specializes in opening the small vessels below the knee and into the foot, which is where kidney disease patients are typically stricken with PAD. Whether you're impacted by peripheral artery disease, kidney health challenges, or simply want to understand the power of family support, this episode is a must-watch! #KidneyHealth #OrganDonation #TheHeartOfInnovation #NationalKidneyMonth #MissMarin2025 #peripheralarterydisease #padsupport #CLI #criticallimbischemia

Last year, 9,000 deceased donor kidneys were discarded due to storage and time limitations. A kidney “life support” machine could change that. Also, the SS United States will join Florida's 4,300 artificial reefs—human-made places for fish and other marine life to live. How do these reefs work?The Effort To Save Thousands Of Donor Kidneys From Being WastedSylvia Miles was diagnosed with lupus in 2006, a chronic autoimmune disease that causes the body's immune system to attack healthy tissue—including her kidneys.Miles, who lives in Indianapolis, was later diagnosed with advanced kidney disease, and was in need of a kidney transplant.Kidney diseases are one of the leading causes of death in the United States with 37 million people living with chronic kidney disease. Together with advanced kidney disease—the later stage of CKD—it cost Medicare billions of dollars in recent years.People like Miles, who need a kidney transplant, wait an average of five years—often on dialysis.But despite the long waitlists and organ shortages, around 9,000 kidneys from deceased donors last year were discarded due to perceived issues with their viability. A new Indiana-based organization, 34 Lives, is working to limit that waste and rehabilitate the organs.Read the rest of this article on sciencefriday.com.Ocean Liner SS United States Will Become An Artificial ReefThis week, after a notable career, the SS United States, a 1950s ocean liner, took her sunset cruise. Like many retirees, the ship is heading south—from Philadelphia to Florida—where she'll be reinventing herself. In this next chapter, the SS United States will have new passengers: fish and other marine creatures. The ship will be sunk to the bottom of the sea and turned into an artificial reef, joining more than 4,300 artificial reefs off the coast of Florida.Other sunken ships have become artificial reefs in the past, which have helped boost marine life as well as scuba diving and fishing tourism. Host Flora Lichtman speaks with Scott Jackson, a regional specialized agent with the Florida Sea Grant and University of Florida IFAS extension, about the science behind artificial reefs, and what has been learned from decades of research.Transcripts for each segment will be available after the show airs on sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.